Stephens Consulting, LLC Cogent Biosciences, Inc. Transaction History
Stephens Consulting, LLC
- $399 Billion
- Q1 2025
A detailed history of Stephens Consulting, LLC transactions in Cogent Biosciences, Inc. stock. As of the latest transaction made, Stephens Consulting, LLC holds 60 shares of COGT stock, worth $262. This represents 0.0% of its overall portfolio holdings.
Number of Shares
60Holding current value
$262% of portfolio
0.0%Shares
1 transactions
Others Institutions Holding COGT
# of Institutions
191Shares Held
104MCall Options Held
157KPut Options Held
439K-
Kynam Capital Management, LP Princeton, NJ9.11MShares$39.8 Million4.5% of portfolio
-
Black Rock Inc. New York, NY7.29MShares$31.9 Million0.0% of portfolio
-
Tcg Crossover Management, LLC Palo Alto, CA6.96MShares$30.4 Million8.87% of portfolio
-
Commodore Capital LP New York, NY6.88MShares$30.1 Million5.38% of portfolio
-
Fairmount Funds Management LLC Philadelphia, PA6.23MShares$27.2 Million9.76% of portfolio
About Cogent Biosciences, Inc.
- Ticker COGT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 65,758,300
- Market Cap $287M
- Description
- Cogent Biosciences, Inc., a biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes CGT9486, a selective tyrosine kinase inhibitor designed to inhibit the KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found ...